MELVILLE, N.Y., Oct. 4, 2017 /PRNewswire/ -- Henry Schein Medical today announced its agreement with Cerebral Assessment Systems (CAS) to distribute Cognivue®, the first computerized cognitive assessment screening device cleared by the Food and Drug Administration to detect early signs of dementia. Cognivue helps practitioners to monitor current brain health and to monitor future reversible dementia treatments commonly caused by sleep disorders, infection, systemic illness, and mood disorders, enhancing the ability of patients and their families to plan for the future. Cognivue will be on display at Henry Schein’s Medical Expo, which takes place on October 24-25 in Nashville, TN.
Cognivue is a fully automated solution that displays controlled visual stimuli on a computer screen, helping practitioners conduct a quantitative analysis of brain health to derive a composite score of overall brain functional integrity. The results are summarized on an easily interpreted report that is stored in the cloud, and provides a single quantitative score of brain health, enabling physicians to identify potential issues that can be addressed before problems get worse. Dementia includes a broad range of symptoms associated with a decline in memory or other cognitive abilities, the most common form of which is Alzheimer’s disease.
“We are excited to work with CAS to deliver advanced technology solutions that our customers can rely on for assessing serious health issues among patients,” said Bridget Ross, President, Global Medical Group. “Our team is committed to not only leveraging our strong distribution network to help health care professionals gain greater access to this innovative technology, but also working with forward-thinking leaders such as CAS, to help practitioners focus on delivering high-quality patient care for dementia.”
Created by Dr. Charles Duffy, based on his 20 years of neurophysiological and psychophysical research, Cognivue monitors and measures how the brain processes information, producing fast and accurate results of patient’s visual and motor capabilities. The test is customized based on the individual patient, calibrating levels of difficulty based on how well a patient’s brain is performing.
“Routine measurement of cognitive function should be available to all patients in order to detect discrepancies in brain functionality and then act on them as soon as possible,” said Dr. Duffy. “With Henry Schein Medical, our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken. Although an early diagnosis does not solve the cure, minimizing the toll dementia takes on patients - by addressing some of the potential causes associated with this condition - is the next best option.”
To learn more visit, http://cerebralassessmentsystems.com/henry-schein/ or watch a video, entitled, Cognivue Technology: Bringing Cognitive Care to Primary Care.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is the world’s largest provider of health care products and services to office-based dental animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein employs more than 21,000 Team Schein Members and serves more than 1 million customers.
The company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.
Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 32 countries. The company’s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.
About Cerebral Assessment Systems, Inc.
CAS, under the direction of Charles Duffy, MD, Ph.D., with offices in Rochester New York, is a medical device company engaged in researching and commercializing automated solutions for the routine measurement and monitoring of brain health. CAS has over 18 issued patents, 6 pending and extensive, on-going research. Cognivue® is the world’s first FDA-cleared, computer-based solution for primary care physicians to routinely measure and monitor brain health and detect early signs of impairment. http://www.cerebralassessmentsystems.com.
View original content:http://www.prnewswire.com/news-releases/henry-schein-medical-to-distribute-cognivue-the-first-automated-screening-device-cleared-to-detect-early-signs-of-dementia-300530275.html
SOURCE Henry Schein, Inc.
